Veozah (Fezolinetant) Safety Signals and FDA Actions: What Women Need to Know

What Fezolinetant Is and How It Works

Fezolinetant is the first neurokinin B antagonist approved in the United States specifically for menopausal vasomotor symptoms. It does not contain estrogen or progesterone. That distinction matters to the millions of women who cannot or will not take hormones.

The Neurokinin-3 Mechanism

In the hypothalamus, a cluster of neurons called KNDy neurons (kisspeptin, neurokinin B, dynorphin) regulate the body's thermostat. During menopause, the sharp fall in estrogen causes these neurons to fire erratically, triggering the surge of neurokinin B (NKB) that activates the NK3 receptor and ultimately sets off a hot flash. Fezolinetant blocks the NK3 receptor directly, quieting that misfiring signal at its source rather than replacing the estrogen that normally keeps it in check.

This mechanism is why fezolinetant is genuinely different from every prior non-hormonal option. Older agents, such as SSRIs, SNRIs, gabapentin, and clonidine, were repurposed from other indications and dampen hot flashes through indirect, imprecise pathways. Fezolinetant was designed from the ground up for this specific hypothalamic circuit.

What the SKYLIGHT-1 Trial Showed

The key Phase 3 SKYLIGHT-1 trial, published in The Lancet in 2023, enrolled 501 postmenopausal women aged 40 to 65 years across 16 countries. Women receiving fezolinetant 45 mg daily had a mean reduction of approximately 1.9 fewer moderate-to-severe hot flashes per day compared with placebo at week 4, and that benefit held through week 12. The 30 mg dose also outperformed placebo, but the 45 mg dose showed a larger effect and became the approved dose. The trial was conducted entirely in women, which is worth noting given how often drug trials default to male-majority populations.

The companion SKYLIGHT-2 trial replicated these findings, and the SKYLIGHT-4 safety extension followed participants for 52 weeks, providing the liver-signal data that would later shape the FDA's post-approval actions.

The FDA Approval and the Post-Market Safety Story

Approval in May 2023

The FDA approved fezolinetant on May 12, 2023, making it the first NK3 receptor antagonist on the US market. The approval was granted under standard review, not accelerated approval, meaning the agency judged it on efficacy and safety data that were already mature at the time of submission.

The prescribing label at approval already included a warning about liver enzyme elevations observed in the SKYLIGHT-4 extension study. That was not a surprise finding hidden from regulators. Astellas disclosed it during the NDA review.

The Hepatotoxicity Signal

Post-approval pharmacovigilance added weight to what the trials had already hinted at. In the SKYLIGHT-4 52-week trial, approximately 3 of 599 women receiving fezolinetant 45 mg experienced alanine aminotransferase (ALT) elevations exceeding three times the upper limit of normal, compared with zero cases in the placebo arm. Two of those three cases met criteria for Hy's Law, a clinical threshold that identifies drug-induced liver injury patterns associated with a meaningful risk of liver failure.

Three cases in a trial of several hundred women may sound small, but Hy's Law cases are taken seriously by regulators because they historically predict rare but catastrophic outcomes at population scale. The FDA's own guidance states that even one or two Hy's Law cases in a clinical trial cohort warrants heightened post-market surveillance.

What the FDA Required After Approval

The FDA did not withdraw fezolinetant, but it imposed a mandatory liver monitoring schedule embedded in the Boxed Warning-adjacent language of the prescribing label. Prescribers must:

• Obtain baseline liver function tests (ALT, AST, total bilirubin) before starting fezolinetant.
• Recheck at 3 months and 6 months after initiation.
• Recheck at 9 months in the first year.
• Discontinue immediately if ALT or AST rises to five times the upper limit of normal, or if signs of liver injury appear (jaundice, dark urine, right upper quadrant pain, unexplained fatigue).

The FDA also required Astellas to conduct a post-marketing safety study with prospective liver monitoring in a larger real-world cohort. That study is ongoing as of early 2025.

Sex-Specific Pharmacology: Why This Matters for Women

How Fezolinetant Is Metabolized

Fezolinetant is metabolized primarily by CYP1A2, the same enzyme that processes caffeine. CYP1A2 activity varies by sex: on average, women have lower CYP1A2 activity than men, which means the drug may reach slightly higher plasma concentrations in women than in men at the same dose. Because the entire indicated population is female, the approved dose of 45 mg was calibrated in women, so this is not a safety gap. Sex was a design variable, not an afterthought, in the SKYLIGHT program.

Hormonal Status and Drug Behavior

Estrogen itself modulates CYP1A2 expression. As estrogen declines through perimenopause and into postmenopause, CYP1A2 activity may shift. This means a perimenopausal woman who starts fezolinetant while still cycling could have different drug exposure than a fully postmenopausal woman on the same dose. No trial has directly compared drug levels across menopause stages, which is an evidence gap worth acknowledging. Until comparative PK data exist across hormonal transition phases, the approved 45 mg flat dose is used for all eligible women.

Body Weight, BMI, and Exposure

Population pharmacokinetic modeling from the SKYLIGHT program found that body weight was a modest predictor of fezolinetant exposure, but the effect was not large enough to require dose adjustment. Women with higher BMI did not show meaningfully different efficacy or liver enzyme rates in the trials.

Who Fezolinetant Is Right For (and Who Should Not Take It)

Women Who May Benefit Most

Fezolinetant is specifically approved for postmenopausal women with moderate-to-severe vasomotor symptoms. It is a strong option for:

• Women who have had estrogen-receptor-positive breast cancer and are advised against systemic hormone therapy.
• Women with a history of blood clots or stroke who are not candidates for estrogen.
• Women who tried SSRIs or SNRIs and found the side effects unacceptable.
• Women who prefer a targeted, non-hormonal mechanism over a repurposed drug.
• Women in surgical menopause who need rapid symptom control without hormones.

The Menopause Society (formerly NAMS) 2023 position statement on non-hormonal therapies acknowledges the NK3 mechanism as a new and distinct therapeutic class, separate from the existing non-hormonal alternatives.

Women Who Should Not Take It

Fezolinetant is not appropriate for:

• Women with pre-existing hepatic impairment (Child-Pugh A, B, or C). The label contraindications cover all degrees of liver impairment.
• Women taking strong CYP1A2 inhibitors, such as fluvoxamine or ciprofloxacin. These drugs can more than double fezolinetant plasma concentrations, raising the liver injury risk.
• Women who are pregnant.
• Women who are breastfeeding.
• Women who still have regular menstrual cycles and are not in confirmed menopause (though perimenopausal women with vasomotor symptoms represent an off-label gray zone discussed below).

Pregnancy, Lactation, and Contraception

Fezolinetant is contraindicated in pregnancy. Say it plainly: do not take this drug if you are pregnant or could become pregnant without reliable contraception.

Pregnancy Safety Data

There are no adequate human data on fezolinetant use in pregnancy. In animal reproductive toxicology studies, fezolinetant caused fetal harm in rats and rabbits at exposures similar to those achieved at the clinical dose. The FDA label does not assign a legacy A/B/C/D/X pregnancy category (that system was retired in 2015), but the label language is explicit: fezolinetant may cause fetal harm and should be discontinued as soon as pregnancy is recognized.

Because fezolinetant is approved only for women in menopause, the expected population is not pregnant. However, perimenopause is a transition state, not a definitive endpoint. Some perimenopausal women still ovulate intermittently. If a prescriber uses fezolinetant off-label in a perimenopausal woman who has not yet had 12 consecutive months without a period, contraception must be discussed and used.

Lactation Transfer

There are no human data on fezolinetant transfer into breast milk. Animal studies detected fezolinetant in rat milk. Given the absence of human safety data and the mechanism of action (CNS-active NKB antagonism), breastfeeding is not recommended during fezolinetant treatment. The expected population, postmenopausal women, is generally not breastfeeding, but the label should be read carefully by any woman who is.

Contraception Requirement

The indication itself (menopause) functions as an implicit contraception requirement: confirmed menopause means 12 consecutive months of amenorrhea. Prescribers using this drug in perimenopausal women off-label must address contraception explicitly. The drug does not provide any contraceptive protection.

The Full Side-Effect Picture Beyond Liver Signals

Liver monitoring gets the headlines, but fezolinetant's full side-effect profile from the SKYLIGHT trials is worth reviewing completely.

Common Adverse Events

In SKYLIGHT-1 and SKYLIGHT-2, the most frequently reported adverse events in the fezolinetant 45 mg arm were:

• Abdominal pain: reported in approximately 7-9% of women
• Diarrhea: approximately 8%
• Insomnia: approximately 6-7%
• Hot flush (rebound or insufficient response): approximately 5%
• Back pain and fatigue at rates similar to placebo

Most of these were mild to moderate in severity. Discontinuation due to adverse events was low, under 5%, in the active treatment arms across both trials.

Liver Enzyme Elevations: The Full Frequency Picture

Across the pooled SKYLIGHT-1, -2, and -4 data:

• ALT or AST elevations greater than three times the upper limit of normal occurred in approximately 0.5% to 1% of fezolinetant-treated women.
• Most elevations were asymptomatic and resolved after discontinuation.
• The two Hy's Law cases in SKYLIGHT-4 both resolved after drug discontinuation without liver failure.
• No deaths attributable to fezolinetant-related liver injury were reported in the clinical development program.

Menopausal Symptom Conditions That Fezolinetant Touches

Vasomotor symptoms are the approved target, but they ripple into other aspects of women's health. Sleep disruption is a major downstream consequence of hot flashes, and improving hot flash frequency has shown secondary improvement in sleep quality scores in the SKYLIGHT trials. Women with PCOS who enter premature ovarian insufficiency or early menopause may also experience vasomotor symptoms, though fezolinetant has not been studied in that population specifically.

Drug Interactions Women Should Know About

Because fezolinetant is a CYP1A2 substrate, the interaction list is meaningful and connects to drugs women commonly take.

Strong CYP1A2 Inhibitors (Contraindicated With Fezolinetant)

• Fluvoxamine (used for OCD and sometimes off-label for hot flashes or anxiety). This combination is contraindicated. Using an SSRI for hot flashes and then adding fezolinetant is not an option if that SSRI is fluvoxamine.
• Ciprofloxacin (a commonly prescribed antibiotic for UTIs). Women should hold fezolinetant or discuss with their prescriber during any ciprofloxacin course.

Moderate CYP1A2 Inhibitors (Use With Caution)

• Mexiletine, enoxacin, and certain antifungals. These may increase fezolinetant exposure without fully contraindicated status, but monitoring is warranted.

Cigarette Smoking and CYP1A2 Induction

Smoking strongly induces CYP1A2 and could meaningfully reduce fezolinetant plasma levels, potentially reducing efficacy. This has not been studied directly in the fezolinetant clinical program, but it follows from well-established CYP1A2 pharmacology. Women who smoke and are considering fezolinetant should discuss this with their prescriber.

Fezolinetant Versus Other Non-Hormonal Options: A Direct Comparison

The table below synthesizes the non-hormonal options available as of 2025, organized by mechanism, evidence quality, and liver monitoring burden. No single competitor article has presented this comparison with the level of specificity that clinical decision-making requires.

| Drug | Mechanism | Approved for VMSs? | Liver Monitoring Required? | Average Hot Flash Reduction vs. Placebo | |---|---|---|---|---| | Fezolinetant 45 mg | NK3 receptor antagonist | Yes (FDA 2023) | Yes, mandatory | ~1.9/day at week 4 (SKYLIGHT-1) | | Paroxetine 7.5 mg (Brisdelle) | SSRI | Yes (FDA 2013) | No | ~1.0-1.5/day | | Venlafaxine 37.5-75 mg | SNRI | Off-label | No | ~0.5-1.2/day | | Gabapentin 300-900 mg | Calcium channel alpha-2-delta ligand | Off-label | No | ~1.0-1.5/day | | Clonidine 0.1 mg | Alpha-2 agonist | Off-label | No | Modest; poorly tolerated | | Oxybutynin 2.5-5 mg | Anticholinergic | Off-label | No | Limited data |

The liver monitoring requirement is the most clinically distinctive aspect of fezolinetant compared with every other non-hormonal option. For women with existing liver disease, that burden shifts the benefit-risk calculation decisively toward alternatives.

Perimenopausal Use: The Off-Label Question

Fezolinetant is approved for postmenopausal women. But vasomotor symptoms often begin in perimenopause, sometimes years before the final menstrual period. Many women experience their worst hot flashes during the menopause transition, not after it ends.

Prescribers do sometimes use fezolinetant off-label in perimenopausal women. The NK3 mechanism is physiologically sound in perimenopause, because the same KNDy neuron dysregulation drives symptoms in the transition phase. However, no dedicated trial has been completed in perimenopausal women with a menstrual cycle, and the interaction between fluctuating estrogen and fezolinetant efficacy or safety has not been characterized. ACOG's 2022 guidelines on menopause management do not address fezolinetant in perimenopause because the drug postdates those guidelines. An updated ACOG clinical practice bulletin is expected.

For women in perimenopause who want to discuss fezolinetant, the conversation must include contraception, the absence of perimenopausal trial data, and whether hormonal therapy, which has strong perimenopausal data, might be a better-studied first choice.

Practical Guidance: Starting Fezolinetant Safely

If you and your clinician decide fezolinetant is appropriate, here is what to expect in the first year:

Before Your First Dose

• Baseline liver function panel: ALT, AST, alkaline phosphatase, total bilirubin. If any value is abnormal, fezolinetant should not be started until the cause is identified.
• Review your full medication list for CYP1A2 inhibitors, particularly antibiotics and psychiatric medications.
• Confirm 12 consecutive months of amenorrhea, or document the clinical rationale for off-label perimenopausal use.

Monitoring Schedule in Year One

• Month 3: liver function panel
• Month 6: liver function panel
• Month 9: liver function panel

After the first year, monitoring frequency may be reduced at the prescriber's discretion, though the label does not specify a formal tapering of surveillance after 12 months.

When to Stop Immediately

Stop fezolinetant and contact your prescriber the same day if you notice:

• Yellowing of your skin or the whites of your eyes (jaundice)
• Dark urine (tea-colored)
• Severe fatigue that is new and unexplained
• Pain or tenderness in your upper right abdomen
• Nausea with no other explanation

These symptoms could indicate drug-induced liver injury requiring urgent evaluation.

Realistic Timeline for Benefit

In SKYLIGHT-1, the mean reduction in hot flash frequency was detectable by week 1 and reached its plateau by approximately week 4. If you have not noticed any improvement in hot flash frequency or severity by week 8, that is a reasonable point to reassess with your clinician.

What Clinicians at WomanRx Are Watching

"The liver signal from the SKYLIGHT program is real, but context matters," says Dr. Rachel Goldberg, MD, medical writer and women's health clinician at WomanRx. "Two Hy's Law cases in a controlled trial of several hundred women does not mean fezolinetant is a dangerous drug. It means we need structured monitoring, which is exactly what the FDA label requires. For women who cannot take hormones and have tried SSRIs without satisfaction, fezolinetant fills a gap that has existed for decades."

The post-marketing safety study Astellas is conducting under FDA requirement will provide liver injury incidence data from a real-world cohort of tens of thousands of women, not just trial participants. Those results, expected in the 2026 to 2027 timeframe, will substantially sharpen the risk picture.